Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$38.49 - $76.21 $104,038 - $205,995
2,703 Added 21.17%
15,473 $801,000
Q1 2022

May 13, 2022

BUY
$58.27 - $118.99 $744,107 - $1.52 Million
12,770 New
12,770 $928,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $835M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Ergoteles LLC Portfolio

Follow Ergoteles LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ergoteles LLC with notifications on news.